Cargando…

Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer’s disease?

This scientific commentary refers to ‘Distinct brain pathologies associated with Alzheimer’s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis’ by Hirota et al. (https://doi.org/10.1093/braincomms/fcac286) and ‘Predictive blood biomar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saura, Carlos A, Parra-Damas, Arnaldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Scientific Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169699/ https://www.ncbi.nlm.nih.gov/pubmed/37180989 http://dx.doi.org/10.1093/braincomms/fcad142

Ejemplares similares

Tissue Clearing and Expansion Methods for Imaging Brain Pathology in Neurodegeneration: From Circuits to Synapses and Beyond
por: Parra-Damas, Arnaldo, et al.
Publicado: (2020)

In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
por: Toombs, Jamie, et al.
Publicado: (2020)

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

Editorial: Bidirectional Communication Between Synapses and Nucleus in Brain Physiology and Disease
por: Parra-Damas, Arnaldo, et al.
Publicado: (2022)

Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease
por: Saura, Carlos A., et al.
Publicado: (2015)

The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019)

Plasma p-tau217: from ‘new kid’ to most promising candidate for Alzheimer’s disease blood test
por: Teunissen, Charlotte E, et al.
Publicado: (2020)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease
por: Lai, Robert Y. K., et al.
Publicado: (2016)

CSF P-tau 231 as Biomarker in Alzheimer's Disease
por: Mukherjee, Adreesh, et al.
Publicado: (2022)

Connections between ApoE, sleep, and Aβ and tau pathologies in Alzheimer’s disease
por: Sadleir, Katherine R., et al.
Publicado: (2023)

Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice
por: Van der Jeugd, Ann, et al.
Publicado: (2018)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Intersection of pathological tau and microglia at the synapse
por: Vogels, Thomas, et al.
Publicado: (2019)

Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
por: Guerrero-Muñoz, Marcos J., et al.
Publicado: (2015)

CSF p-tau231: A biomarker for early preclinical Alzheimer?
por: Suárez-Calvet, Marc
Publicado: (2022)

Music, memory and mechanisms in Alzheimer’s disease
por: Clark, Camilla N., et al.
Publicado: (2015)

Alzheimer’s disease, cerebrovascular disease and dementia: lump, split or integrate?
por: Biessels, Geert Jan
Publicado: (2022)

Evaluating when (and how) hypertension may be ‘good for your brain’
por: Magaki, Shino D, et al.
Publicado: (2023)

Detecting early changes in Alzheimer’s disease with graph theory
por: Pereira, Joana B
Publicado: (2020)

Preclinical Alzheimer’s disease: how to predict who will decline next year?
por: Hanseeuw, Bernard J, et al.
Publicado: (2023)

Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology
por: Calabresi, Peter A., et al.
Publicado: (2010)

Single-synapse analyses of Alzheimer’s disease implicate pathologic tau, DJ1, CD47, and ApoE
por: Phongpreecha, Thanaphong, et al.
Publicado: (2021)

Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease
por: Yu, Chao-Chao, et al.
Publicado: (2019)

Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
por: Rawat, Priyanka, et al.
Publicado: (2022)

Loss of presenilin function enhances tau phosphorylation and aggregation in mice
por: Soto-Faguás, Carlos M., et al.
Publicado: (2021)

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
por: Horie, Kanta, et al.
Publicado: (2023)

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
por: Newby, Danielle
Publicado: (2022)

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2022)

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
por: Janelidze, Shorena, et al.
Publicado: (2023)

Quantitative postural models as biomarkers of balance in Parkinson’s disease
por: Xiang, Min, et al.
Publicado: (2018)

Everyone needs good neighbours – the intricate relationship between the acetylcholine-receptor channel and its membrane environment
por: Muench, Stephen P.
Publicado: (2017)

CRTC1 mediates preferential transcription at neuronal activity-regulated CRE/TATA promoters
por: Parra-Damas, Arnaldo, et al.
Publicado: (2017)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
por: Hardy, John, et al.
Publicado: (2023)

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2020)

Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease
por: Zhou, Yan, et al.
Publicado: (2018)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
por: Tatebe, Harutsugu, et al.
Publicado: (2017)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5861lah8p4ec9j43b9l7l2rlak